Antonietta Martelli

Antonietta Martelli

Auto-generated profile, based on publicly available information

Antonietta Martelli

Department of Internal Medicine, Division of Clinical Pharmacology and Toxicology, University of Genoa, Viale Benedetto XV, 2, I-16132 Genoa, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
GBGiovanni Brambilla
Giovanni Brambilla
AMAntonietta Martelli
Antonietta Martelli

1 July 2009 in Toxicology
Verified
Journal Article
Closed access
GBGiovanni Brambilla
Giovanni Brambilla
Francesca MattioliFrancesca Mattioli
Francesca Mattioli
AMAntonietta Martelli
Antonietta Martelli

6 January 2012 in Mutagenesis
Verified
Journal Article
Closed access
PDF file
GBGiovanni Brambilla
Giovanni Brambilla
Francesca MattioliFrancesca Mattioli
Francesca Mattioli
LRLuigi Robbiano
Luigi Robbiano
AMAntonietta Martelli
Antonietta Martelli
This review provides a compendium of retrievable results of genotoxicity and animal carcinogenicity studies performed of antibacterial, antiviral, antimalarial and antifungal drugs of long-term or intermittent frequent use. Of the 48 drugs considered, 9 (18.75%) do not have retrievable data, whereas the other 39 (81.25%) have at least one genotoxicity or carcinogenicity tests result. Of these 39 drugs, 24 tested positive in at least one genotoxicity assay and 19 in at least one carcinogenicity assay; 14 of them gave a positive response in both at least one genotoxicity assay and at least one carcinogenicity assay. Concerning the predictivity of genetic toxicology findings for the results of long-term carcinogenesis assays, of 23 drugs with both genotoxicity and carcinogenicity data: 2 (8.7%) were neither genotoxic nor carcinogenic, 2 (8.7%) tested positive in at least one genotoxicity assay but were non-carcinogenic, 4 (17.4%) tested negative in genotoxicity assays but were carcinogenic, and 15 (65.2%) gave a positive response in at least one genotoxicity assay and in at least one carcinogenicity assay. Only 18 (37.5%) of the 48 drugs examined had all data required by present guidelines for testing of pharmaceuticals, but a fraction of them (49%) were developed and marketed prior to the present regulatory climate. In the absence of compelling indications, the prescription of the 19 drugs that are animal carcinogens should be avoided.

1 July 2009 in Pharmacological Research
Verified
Journal Article
Closed access
GBGiovanni Brambilla
Giovanni Brambilla
AMAntonietta Martelli
Antonietta Martelli

1 March 2006 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
GBG Brambilla
G Brambilla
AMA Martelli
A Martelli

17 May 2010 in Mutagenesis
Verified
Journal Article
Closed access
PDF file
GBGiovanni Brambilla
Giovanni Brambilla
Francesca MattioliFrancesca Mattioli
Francesca Mattioli
AMAntonietta Martelli
Antonietta Martelli
This review provides a compendium of retrievable results of genotoxicity and carcinogenicity assays performed on marketed gastrointestinal drugs. Of the 71 drugs considered, 38 (53.5%) do not have retrievable data, whereas the other 33 (46.5%) have at least one genotoxicity or carcinogenicity test result. Of these 33 drugs, 15 tested positive in at least one genotoxicity assay and 13 in at least one carcinogenicity assay; 8 of them gave a positive response in both at least one genotoxicity assay and at least one carcinogenicity assay. Concerning the predictivity of genetic toxicology findings for the result(s) of long-term carcinogenesis assays, of 21 drugs with both genotoxicity and carcinogenicity data: 6 (28.6%) are neither genotoxic nor carcinogenic, 2 (9.5%) tested positive in at least one genotoxicity assay but were non-carcinogenic, 5 (23.8%) tested negative in genotoxicity assays but were carcinogenic and 8 (38.1%) gave a positive response in at least one genotoxicity assay and in at least one carcinogenicity assay. Only 12 (16.9%) of the 71 drugs examined have all data required by present guidelines for testing of pharmaceuticals, but a large fraction of them were developed and marketed prior the present regulatory climate.